Orthofix Medical Inc.
NASDAQ:OFIXMedical - Devices
+$0.03 today
- Market cap
- $269.42M
- Beta
- 0.71
- P/E (TTM)
- -6.2
- EPS (TTM)
- -$1.48
Volume 0.40M
Average 0.38M
OFIX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Orthofix Medical Inc.NASDAQ: OFIX
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q1 FY2026 stock-based compensation of $6.53M rose 1.0% year over year, behind the +40.4% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 68.5% from the prior quarter. Over 3 fiscal years it compounded at +15.9% a year.
Context
- Stock-based compensation amounted to 3.5% of revenue in FY2025, down 0.6 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +1.0% toward the trailing-twelve-month pace of +40.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 28.69M USD
- Year-over-year change
- -11.6%
- 4-year CAGR
- +16.8%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.69M | -11.6% |
| FY2024 | 2024-12-31 | 32.46M | -9.1% |
| FY2023 | 2023-12-31 | 35.71M | +93.6% |
| FY2022 | 2022-12-31 | 18.44M | +19.5% |
| FY2021 | 2021-12-31 | 15.43M | — |
Stock-Based Compensation vs competitors
How OFIX compares with its peers on the latest reported figures
- OFIX's LTM Mar 2026 stock-based compensation of $42.3M is the largest of the 11 companies compared; the peer median is $13.02M.
- Its year-over-year change of +40.4% is the 2nd highest of 11, against a peer median of -11.1%.
- Stock-based compensation amounts to 5.1% of revenue for OFIX, versus a peer median of 12.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $42.3M | +40.4% | +15.9% | 5.1% | |
| LTM Mar 2026 | $27.48M | -5.7% | +25.8% | 31.9% | |
| LTM Mar 2026 | $24.89M | -2.4% | +3.4% | 12.1% | |
| LTM Mar 2026 | $23.96M | +203.5% | +10.1% | — | |
| LTM Mar 2026 | $22.69M | +4.1% | -18.0% | 22.1% | |
| LTM Mar 2026 | $13.53M | -11.4% | +13.5% | 737.0% | |
| LTM Mar 2026 | $12.5M | -10.7% | -7.5% | 1.7% | |
| LTM Apr 2026 | $10.9M | -28.8% | +2.3% | 1.3% | |
| LTM Mar 2026 | $9.91M | -11.7% | -13.4% | 2.4% | |
| LTM Mar 2026 | $9.59M | -84.2% | -19.1% | 6.0% | |
| LTM Mar 2026 | $5.51M | -51.1% | -18.0% | 26.0% | |
| Peer median (excluding OFIX) | $13.02M | -11.1% | -2.6% | 12.1% | |
Competitors are the stored peer set for OFIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (38.38M) | (19.75M) | (151.4M) | (126M) | (92.19M) |
| Depreciation & Amortization | 33.1M | 32.08M | 60.6M | 75.96M | 83.26M |
| Deferred Income Tax | 24.48M | 314K | 579K | 1.88M | 223K |
| Stock-Based Compensation | 15.43M | 18.44M | 35.71M | 32.46M | 28.69M |
| Change in Working Capital | (18.1M) | (29.24M) | (53.96M) | (19.25M) | (21.5M) |
| Accounts Receivables | (7.05M) | (6.74M) | (10.41M) | (9.53M) | (1.58M) |
| Inventory | 619K | (18.13M) | (58.05M) | (5.55M) | (10.75M) |
| Accounts Payables | 4.25M | 2.28M | 8.64M | (5.57M) | 2.6M |
| Other Working Capital | (15.93M) | (6.65M) | 5.86M | 1.39M | (11.77M) |
| Other Non-Cash Items | 1.95M | (13.39M) | 62.72M | 60.74M | 54.84M |
| Operating Cash Flow | 18.48M | (11.54M) | (45.75M) | 25.79M | 33.35M |
| Capital Expenditures | (19.59M) | (23.16M) | (62.05M) | (34.88M) | (34.63M) |
| Acquisitions (Net) | 0 | (1.5M) | 29.42M | 0 | 0 |
| Purchases of Investments | (2.17M) | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 126K | 0 | 7.4M | 0 |
| Other Investing Activities | (1.25M) | (1.37M) | (500K) | (100K) | (34.6M) |
| Investing Cash Flow | (23.01M) | (24.53M) | (33.13M) | (27.58M) | (34.6M) |
| Debt Repayment | (537K) | (2.59M) | 67.95M | 54.39M | (762K) |
| Common Stock Issued | 8.82M | 4.34M | 5.13M | 6.26M | 5.93M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (11.91M) | (1.82M) | (7.75M) | (9.94M) | (5.95M) |
| Financing Cash Flow | (3.62M) | (78K) | 65.32M | 50.71M | (786K) |
| Effect of Forex Changes | (815K) | (997K) | 619K | (938K) | 1.41M |
| Net Change in Cash | (8.97M) | (37.15M) | (12.94M) | 47.98M | (623K) |
| Free Cash Flow | (1.12M) | (34.7M) | (107.8M) | (9.09M) | (1.28M) |
Orthofix Medical Inc.
NASDAQ:OFIX
Intrinsic Alpha fair value
Locked
Current Price
$6.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.